14th Sep 2015 06:46
LONDON (Alliance News) - Hutchison China MediTech Ltd said Monday it will present results from its phase II clinical trial of fruquintinib in metastatic colorectal cancer at the European Cancer Congress in Vienna at the end of the month.
In March, the company announced that the study met its primary endpoint of progression free survival, showing superiority compared to a placebo, and was well tolerated in the study. 71 patients were enrolled in the trial, of which 47 patients received fruiquintinib, whilst 24 patients received the placebo.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
Hutchmed